Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy

Area of Science:

• Oncology
• Genetics
• Immunotherapy

Background:

• Defects in DNA damage response (DDR) genes impair DNA repair, leading to genomic instability and cancer development.
• Altered DDR genes can serve as biomarkers for patient selection in immune checkpoint blockade (ICB) therapy.
• Targeting DDR offers therapeutic strategies via synthetic lethality and modulation of the cGAS-STING-interferon pathway.

Purpose of the Study:

• To review the mechanisms of DDR and their role in cancer therapy.
• To discuss the interplay between DDR-targeting and ICB therapies.
• To highlight contemporary clinical trials involving DDR-targeting and ICB in specific cancers.

Main Methods:

• Literature review of DDR mechanisms.
• Analysis of synthetic lethality principles in cancer treatment.
• Review of immune checkpoint blockade (ICB) therapy mechanisms.
• Compilation of data from contemporary clinical trials.

Main Results:

• DDR gene alterations are implicated in cancer development and can predict response to ICB.
• Synthetic lethality offers a targeted approach for DDR-deficient cancers.
• DDR modulation can enhance anti-tumor immunity through the cGAS-STING pathway.
• Clinical trials are exploring combined DDR-targeting and ICB strategies.

Conclusions:

• Targeting DDR, particularly in conjunction with ICB, presents a promising avenue for novel cancer therapeutics.
• Understanding DDR mechanisms is crucial for developing effective synthetic lethality and immunotherapy strategies.
• Further clinical investigation is warranted to optimize combined DDR-targeting and ICB treatments for various cancers.